Response Assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology Recommendations for the Clinical Use of PET Imaging in Gliomas

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2016 Apr 24

PMID 27106405

Citations 346

Authors

Nathalie L Albert

Michael Weller

Bogdana Suchorska

Norbert Galldiks

Riccardo Soffietti

Michelle M Kim

Christian La Fougere

Whitney Pope

Ian Law

Javier Arbizu

Marc C Chamberlain

Michael Vogelbaum

Ben M Ellingson

Joerg C Tonn

Affiliations

Soon will be listed here.

Abstract

This guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose ((18)F-FDG) and amino acid tracers ((11)C-MET, (18)F-FET, and (18)F-FDOPA). An increasing number of studies have been published on PET imaging in the setting of diagnosis, biopsy, and resection as well radiotherapy planning, treatment monitoring, and response assessment. Recommendations are based on evidence generated from studies which validated PET findings by histology or clinical course. This guideline emphasizes the clinical value of PET imaging with superiority of amino acid PET over glucose PET and provides a framework for the use of PET to assist in the management of patients with gliomas.

Citing Articles

Quantitative evaluation of neuroradiological and morphometric alteration of inferior Fronto-Occipital Fascicle across different brain tumor histotype: an Italian multicentric study.

Altieri R, Bianconi A, Caneva S, Cirillo G, Cofano F, Corvino S Acta Neurochir (Wien). 2025; 167(1):71.

PMID: 40072663 PMC: 11903521. DOI: 10.1007/s00701-025-06488-6.

GCN5-targeted dual-modal probe across the blood-brain barrier for borders display in invasive glioblastoma.

Zheng H, Zhang L, Bai X, Zhu J, Liu S, Ke Y Nat Commun. 2025; 16(1):2345.

PMID: 40057495 PMC: 11890771. DOI: 10.1038/s41467-025-57598-9.

A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma.

Ellingson B, Okobi Q, Chong R, Plawat R, Zhao E, Gafita A Neurooncol Adv. 2025; 7(1):vdaf022.

PMID: 40051661 PMC: 11883343. DOI: 10.1093/noajnl/vdaf022.

An effective MRI perfusion threshold based workflow to triage additional F-FET PET in posttreatment high grade glioma.

Kadali K, Nierobisch N, Maibach F, Heesen P, Alcaide-Leon P, Hullner M Sci Rep. 2025; 15(1):7749.

PMID: 40044711 PMC: 11882894. DOI: 10.1038/s41598-025-90472-8.

Targeted liquid biopsy for brain tumors.

Izhar M, Ahmad Z, Moazzam M, Jader A J Liq Biopsy. 2025; 6:100170.

PMID: 40027302 PMC: 11863980. DOI: 10.1016/j.jlb.2024.100170.

References

Kracht L, Miletic H, Busch S, Jacobs A, Voges J, Hoevels M . Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21):7163-70. DOI: 10.1158/1078-0432.CCR-04-0262. View

Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A . Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004; 45(8):1293-8. View

Nioche C, Soret M, Gontier E, Lahutte M, Dutertre G, Dulou R . Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT. Clin Nucl Med. 2013; 38(2):81-7. DOI: 10.1097/RLU.0b013e318279fd5a. View

Tripathi M, Sharma R, Dsouza M, Jaimini A, Panwar P, Varshney R . Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2010; 34(12):878-83. DOI: 10.1097/RLU.0b013e3181becfe0. View

Popperl G, Kreth F, Mehrkens J, Herms J, Seelos K, Koch W . FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007; 34(12):1933-42. DOI: 10.1007/s00259-007-0534-y. View

Galldiks N, Ullrich R, Schroeter M, Fink G, Jacobs A, Kracht L . Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2009; 37(1):84-92. PMC: 2791473. DOI: 10.1007/s00259-009-1219-5. View

Ewelt C, Floeth F, Felsberg J, Steiger H, Sabel M, Langen K . Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg. 2011; 113(7):541-7. DOI: 10.1016/j.clineuro.2011.03.008. View

Gross M, Weber W, Feldmann H, Bartenstein P, Schwaiger M, Molls M . The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys. 1998; 41(5):989-95. DOI: 10.1016/s0360-3016(98)00183-7. View

Walter F, Cloughesy T, Walter M, Lai A, Nghiemphu P, Wagle N . Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. J Nucl Med. 2012; 53(3):393-8. DOI: 10.2967/jnumed.111.095711. View

10.

Glaudemans A, Enting R, Heesters M, Dierckx R, van Rheenen R, Walenkamp A . Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2012; 40(4):615-35. DOI: 10.1007/s00259-012-2295-5. View

11.

Omuro A, Leite C, Mokhtari K, Delattre J . Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006; 5(11):937-48. DOI: 10.1016/S1474-4422(06)70597-X. View

12.

Hutterer M, Nowosielski M, Putzer D, Jansen N, Seiz M, Schocke M . [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol. 2013; 15(3):341-51. PMC: 3578481. DOI: 10.1093/neuonc/nos300. View

13.

Charnley N, West C, Barnett C, Brock C, Bydder G, Glaser M . Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 66(2):331-8. DOI: 10.1016/j.ijrobp.2006.04.043. View

14.

Thon N, Kunz M, Lemke L, Jansen N, Eigenbrod S, Kreth S . Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. Int J Cancer. 2014; 136(9):2132-45. DOI: 10.1002/ijc.29259. View

15.

Fougere C, Suchorska B, Bartenstein P, Kreth F, Tonn J . Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011; 13(8):806-19. PMC: 3145468. DOI: 10.1093/neuonc/nor054. View

16.

Popperl G, Goldbrunner R, Gildehaus F, Kreth F, Tanner P, Holtmannspotter M . O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005; 32(9):1018-25. DOI: 10.1007/s00259-005-1819-7. View

17.

Brandsma D, van den Bent M . Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009; 22(6):633-8. DOI: 10.1097/WCO.0b013e328332363e. View

18.

Jansen N, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A . Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014; 55(2):198-203. DOI: 10.2967/jnumed.113.122333. View

19.

Arbizu J, Tejada S, Marti-Climent J, Diez-Valle R, Prieto E, Quincoces G . Quantitative volumetric analysis of gliomas with sequential MRI and ¹¹C-methionine PET assessment: patterns of integration in therapy planning. Eur J Nucl Med Mol Imaging. 2012; 39(5):771-81. DOI: 10.1007/s00259-011-2049-9. View

20.

Mehrkens J, Popperl G, Rachinger W, Herms J, Seelos K, Tatsch K . The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol. 2008; 88(1):27-35. DOI: 10.1007/s11060-008-9526-4. View